Description: Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Home Page: www.ardelyx.com
400 Fifth Avenue
Waltham,
MA
02451
United States
Phone:
510 745 1700
Officers
| Name | Title |
|---|---|
| Mr. Michael G. Raab | President, CEO & Director |
| Ms. Elizabeth A. Grammer Esq. | Chief Legal & Administrative Officer and Secretary |
| Dr. Laura A. Williams M.D., M.P.H. | Chief Medical Officer |
| Mr. Justin A. Renz CPA, MBA | Chief Financial & Operations Officer |
| Mr. Joseph Reilly | Senior VP of Finance & Principal Accounting Officer |
| Ms. Caitlin Lowie | Vice President of Corporate Communications & Investor Relations |
| Mr. Mike Kelliher | Executive Vice President of Corporate Development & Strategy |
| Ms. Charon Spencer Sr. | Chief Human Resources Officer |
| Mr. David P. Rosenbaum | Chief Development Officer |
| Mr. Robert C. Blanks | Chief Regulatory Affairs & Quality Assurance Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.1061 |
| Price-to-Sales TTM: | 4.9206 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 267 |